Recurrence of steroid-resistant nephrotic syndrome in kidney trans. plants is associated with increased acute renal failure and acute rejection. We performed 73 kidney transplants in 51 patients with steroid-resistant nephrotic syndrome (SRNS) with focal segmental glomerular sclerosis (FSG) ages 18.4 12.8 (X SD) years. Recurrence of SRNS, defined by rapid onset of proteinuria, hypoalbuminemia and/or >95% epithelial cell foot process effacement with or without the presence of FSG, occurred in 26 grafts in 16 patients. Acute renal failure (ARF) occurred in 16 of 26 (61.5%) grafts with recurrence versus 7 of 47 (14.9%) grafts without recurrence (P < 0.0001). ARF occurred in 4 of 9 (44.4%) living-related donor (LRD) recipients with recurrence and 3 of 21 (12.5%) LRD recipients without recurrence (NS). ARF in cadaver donor (CAD) recipients with recurrence was 12 of 17 (70.5%) versus 4 of 23 (17.4%) without recurrence (P < 0.0001). ARF was also higher in LRD or CAD with recurrence than in a control group of non-SRNS patients matched for age, sex and time of transplantation. Graft survival at one year was lower in patients with recurrence and ARF [4 of 16 (25%)] compared to patients with recurrence and no ARF [9 of 11 (82%), P < 0.011. There was no difference in graft survival in patients without recurrence who did or did not have ARF. One or more acute rejection episodes occurred in all 16 patients with ARF and recurrence, in all 7 patients with ARF without recurrence, and in 7 of 10 patients with recurrence without ARF compared with only 11 of 40 (28%) of patients with neither recurrence nor ARF (P < 0.0001, <0.001 and <0.04, respectively). A loglinear model showed associations between acute rejection and ARF (P < 0.01), recurrence and ARF (P = 0.05), and recurrence and acute rejection (P < 0.025). Twelve of 16 (75%) of grafts with both recurrence and ARF versus 4 of 40(10%) of grafts with neither recurrence nor ARF were lost in association with acute rejection in the first two post-transplant years (P < 0.0001). Only one graft was lost from recurrence of SRNS, per se. Thus, recurrence of SRNS is associated with an increased incidence of ARF, and both ARF and recurrence are associated with greater risks of acute rejection. The increased graft loss in recurrence is primarily due to acute rejection. As has been speculated for ARF, recurrence may result in graft changes which stimulate acute rejection.
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Patients transplanted for end-stage renal failure developing consequent to steroid resistant nephrotic syndrome (SRNS) with focal segmental glomerulosclerosis (FSG) are at risk for whose primary renal disease took less than three years to proceed from onset to terminal uremia and patients whose native kidneys had diffuse or focal mesangial cell proliferation were at increased risk of recurrence of proteinuria in the renal allograft [8, 9] . We had also shown that these two variables, rapid progression to terminal ure ia and mesangial proliferation, were frequently covariables [9] . In addition, we and others have reported increased graft loss in patients with SRNS/FSG and recurrent proteinuria in the renal allograft [3, [7] [8] [9] [10] . However, the cause of this increased in graft loss has not been completely explained. It is known that patients with nephrotic syndrome can be at higher risk for acute renal failure (ARF) [12] [13] [14] [15] [16] [17] [18] most often, as reviewed by Smith and Hayslett, accompanied by acute tubular necrosis (ATN) [18] . Further, it has been suspected that ATN may be associated with an increased risk of acute rejection in renal allograft recipients had previously reported, based on a chart review study, that about one-half of the graft loss in patients with recurrence was due to rejection and one-half was due to recurrence per se [22] . However, in a study initiated to explore our clinical suspicion suggesting a high frequency of ARF in patients with recurrent SRNS, we encountered an inordinate incidence of acute rejection. This resulted in a complete re-analysis of our SRNS/FSG patient material, including a review of all relevant renal allograft pathology specimens. We report that patients with recurrence of SRNS have a markedly increased rate of ARF and renal allograft loss from rejection compared to patients without recurrence and that these two transplant complications may be separate risk factors.
Methods

Patients
Since 1965 we have performed 73 renal allograft transplants in 51 patients (25 female) with SRNS/FSG. Their ages at the time of initial transplantation was 18.4 12.8 years (X SD). Thirty-three of these allografts were from living-related donors (LRD) and 40 from cadaver donors (CAD). All of the patients previously described in our papers detailing risk factors for (1) clinical recurrence with the post-transplant development of hypoalbuminemia (serum albumin <2.5 g/dl) and/or proteinuria, 1 g/m2/24 hr, within 3 months of transplantation in the absence of clinical or histological evidence of acute rejection. All patients classified as recurrent disease based on proteinuria had at least 5 g/24 hr of urinary protein; (2) histologic recurrence with 95 to 100% foot process obliteration by electron microscopy [8, 9] ; no patients were classified as having histologic recurrence with FSG by light microscopy in the absence of proteinuria as defined above (Table 1) .
Acute renal failure. ARF is defined as post-transplant renal failure with oliguria ( 1 cc/kg/hr) and uremia requiring dialysis support during the first post-transplant week. Patients were judged not to have ARF if renal insufficiency was determined to result from hyperacute, accelerated or acute rejection, or vascular or urologic complications. Acute rejection. The diagnosis of acute rejection was applied only to patients meeting renal biopsy criteria which we have previously described in detail [23] . Graft loss due to acute rejection was defined as one or more biopsy-proven episodes of acute renal allograft rejection resulting in sufficient loss of renal function or perpetuation of primary nonfunction so as to require chronic dialysis and/or retranspiantation.
Graft loss from recurrent FSG. To qualify for this category, graft failure with advanced renal insufficiency would have occurred in association with marked glomerular abnormalities of FSG and global glomerular sclerosis in the absence of pathologic findings of acute and chronic rejection. This criterion strictly confines graft loss from recurrent FSG to situations in which glomerular destruction from recurrent disease is clearly the dominant reason for graft failure. The adoption of this strict definition resulted in reclassification of some patients we had previously reported as having had graft loss due to recurrent disease [9, 22] 
Results
Incidence and criteria for recurrence of SRNS Twenty-six grafts in 16 patients were classified as having recurrence of SRNS (Table 1 ). In 25 grafts the diagnosis was based upon the documentation of heavy proteinuria in the first three months post-transplantation. However, in 20 of these 25 grafts there was pathologic confirmation of this diagnosis, 7 having FSG, 9 having both FSG and extensive foot process fusion and 4 having foot process fusion alone. Thus, in all 11 grafts classified as recurrence of SRNS by the presence of early heavy proteinuria and where electron microscopic material was available, the diagnosis was confirmed by the presence of marked epithelial cell changes. Only in one case of primary graft nonfunction was the diagnosis based on histologic criteria alone, that of extensive foot process fusion (Table 1) . FSG was first detected on biopsies performed between 15 days and 2 years post-transplantation and extensive foot process fusion was noted on biopsies performed within 7 days to 2 months post-transplantation.
Sixteen of the 26 (61.5%) grafts in SRNS patients had ARF. In 37 patients with 47 grafts that did not have recurrent SRNS, the incidence of ARF was 14.9% (P = 0.0001, chi-square).
While the incidence of ARF in cadaver kidneys with recurrence was significantly greater than in cadaver kidneys with no recurrence (P = 0.002, Fisher exact test), this comparison did not reach statistical significance for the LRD recipients (Table  2) . LRD with recurrence and CAD with recurrence both had higher incidences of ARF than their appropriate non-SRNS controls (chi-square P <0.01 and <0.05, respectively, Table 2 ). There were no significant differences in ARF comparing SRNS patients without recurrence and their controls ( Table 2) . There was a trend toward group effects of preservation time on the risk of ARF (P = 0.074, ANOVA). Control group cadaver recipients with ARF had longer preservation times (38 8 hr; N = 12) than those without ARF (25 12 ; N = 22; P < 0.005). There were no other significant group differences.
Donor age did not influence ARF risk (ANOVA P = 0.88).
Renal biopsies were performed during the ARF episodes in 9 renal allografts of SRNS patients between 4 and 30 (median 15) days post-kidney transplantation. Since, in most cases these biopsies were performed when ARF persisted beyond 10 to 14 days and since ARF was usually short lived, most patients did not have biopsies during their ARF episodes. All showed changes consistent with acute tubular necrosis (ATN). In one case immediate post-transplant massive proteinuria was followed, within 36 hours, by ARF. FSG lesions were noted at 15 days post-transplant (see above) and mild acute tubulointerstitial rejection was also noted. One graft showed ATN and moderate acute tubulointerstitial rejection at 21 days posttransplant. This was treated successfully. However, with recovery of graft function, there was increasing proteinuria and, five weeks later, FSG lesions and diffuse foot process fusion was noted on a repeat allograft biopsy.
Graft survival rates at one year and at final follow-up were markedly reduced in grafts with recurrence and ARF compared to grafts with recurrence without ARF (Table 3) . However, there was no difference in graft survival rates at one year or long-term (beyond one year) in kidneys with no recurrence comparing those with to those without ARF (Table 3 ). It is noteworthy that only one of 16 grafts with recurrence and ARF was functioning at the time of this analysis. Control patients with ARF tended to have a lower one year graft survival rate, but this did not reach statistical significance (Table 3) . ARF was also associated with a numerically lower long-term graft survival in controls but this was not statistically significant (Table   3 ).
Six of the 16 grafts with recurrence and ARF (3 in a single patient) were lost when severe acute rejection ensued while the patients were still receiving dialysis support for ARF (Table 4 ).
In two of these grafts massive proteinuria was documented before ARF developed. Five patients had severe nephrotic syndrome with massive proteinuria complicated by rejection episodes and elevated serum creatinine values. This combination led to the patients being extremely ill and to the decision for early graft removal. Chronic rejection, acute rejection and death with functioning graft accounted for the other four graft losses in patients with recurrence and ARF (Table 4) . In contrast, only one patient with recurrence without ARF required early graft removal for massive nephrotic syndrome and early renal dysfunction (Table 4) . Only one patient with recurrence of SRNS actually lost graft function primarily because of destruction of the graft from the redevelopment of lesions of FSG and global glomerular sclerosis without evidence of acute or chronic rejection. The dominant causes of graft loss in patients without recurrence included acute and chronic rejection, death with a functioning graft, and noncompliance ( Table   4 ). As expected, most of the grafts that were lost in controls were destroyed by acute or chronic rejection (Table 4 ).
All 16 patients with recurrence and ARF had one or more acute rejection episodes in the first post-transplant year (Table   5 ). Also, the incidence of acute rejection was increased in patients with recurrence but no ARF and in patients with ARF without recurrence compared to the incidence in grafts with neither of these complications (Table 5) . A log linear model revealed significant associations between recurrence and ARF (P = 0.05), recurrence and rejection (P < 0.025), and rejection and ARF (P < 0.01; Table 5 ). Thus, the incidence of acute rejection was higher in those grafts with recurrence or ARF or both compared to grafts with neither of these complications (Table 5 ). Acute rejection in the first year was also more common in controls with ARF than in SRNS grafts with neither ARF nor recurrence. However, although numerically greater, the incidence of acute rejection in control grafts with ARF was not significantly different from that in control grafts without ARF (Table 5) .
Discussion
Our studies demonstrate a marked increase in the incidence of ARF in patients documented to have recurrence of SRNS by either clinical or histological criteria or both. This increased incidence among SRNS patients was mainly seen in recipients of cadaver kidneys with recurrent SRNS while a similar trend amongst LRD recipients did not reach statistical significance.
However, compared to non-SRNS controls, the increase in ARF in SRNS patients with recurrence was seen in both LRD and CAD recipients. Our data do not allow for definitive dissection as to whether recurrence of SRNS predisposes to ARF or whether ARF is responsible for an increased incidence of recurrence. However, reports of severe ARF occurring in the native kidneys of patients with SRNS following relatively minor provocative events [12] [13] [14] [15] [16] [17] [18] argue that the high incidence of ARF seen in the current study may be consequent to recurrence of SRNS. Certainly, recurrence was noted in the absence of ARF in our patients, indicating that ARF is not a necessary precondition for recurrence of SRNS in the renal allograft. The mechanism(s) whereby recurrence of SRNS might predispose to ARF is unknown. Glomerular filtration rate (GFR) is reduced in patients with nephrotic syndrome [24, 25] and the reduction in GFR is proportional to the severity of glomerular epithelial foot process alterations [26] . Since a marked degree foot process obliteration was seen in all of our patients with recurrence whose biopsies were studied by electron microscopy, it is possible that these epithelial cell changes were associated with reduced GFR. Under these circumstances, the additional renal trauma related to the transplant process per se may have been sufficient to produce the extreme decline in GFR which we (13) 1 (6) 1 (6) -- (20) 1 (10) 1 (10) 1 (10) - (28) 1 (3) 5 (13) - (8) 3 (23) ---13 (25) 1 (2) 6 (12) defined as ARF. The greater incidence of ARF amongst cadaver as compared to LRD recipients with recurrence of SRNS in our study is consistent with this hypothesis. This increased incidence could not be explained by influences of donor age or preservation time of cadaver kidneys in SRNS patient. This study confirmed our [8, 9] and others' [7, 10] previous observations indicating reduced early and long-term survival rates in grafts suffering from recurrence of SRNS. The current study indicates that the highest incidence of graft loss occurred in patients with both ARF and recurrence. In this group of 16 renal allografts, 15 were lost, 14 in association with rejection, and 12 early in the post-transplant course. Six grafts with ARF followed by acute rejection never functioned sufficiently to allow the patient to become dialysis-independent following transplantation. Of the 42 grafts in our series which were lost, only one was lost primarily due to severe progression of focal segmental and global glomerular sclerosis. The remainder were primarily lost consequent to acute and chronic rejection. This conclusion, somewhat at variance with our previous writings on this subject [9, 23] , derives from the current more strict classification of graft loss due to recurrent SRNS/FSG as being limited to patients without histologic evidence of serious acute and/or chronic rejection but with advanced focal segmental and global glomerular sclerosis. Further, the methodology of the current study involved a review of all histologic materials, resulting in some changes in the assignment of causes of graft loss compared to our earlier studies which depended on chart reviews.
Both recurrence of SRNS and ARF were independently related to an increased incidence of one or more acute rejection episodes in the first post-transplant year. An increase in the incidence of acute rejection episodes with an associated increase in early graft loss has been previously reported in patients with post-transplant ARF [19] [20] [21] , and our control patients evidenced similar trends. In addition, our studies indicate that SRNS recurrence, per se, is also associated with increased acute rejection risk. The pathogenesis of this increased acute rejection risk is unknown. Possibly acute renal injury is associated with the increased immunogenicity of the kidney [21] , perhaps, as suggested by Shoskes, Parfrey and Halloran, [27] , through increased expression of MHC antigens in the renal graft, leading to more efficient T cell recognition and effector response [28, 29] [32, 33] , perhaps beginning prior to transplantation, should be considered for these high risk patients. Second, great pains should be taken to prevent ARF following renal transplantation. Third, once oliguria has developed, there is little to be gained by aggressive fluid administration and diuretic therapy (personal observations) and it is best to avoid creating situations of fluid overload in such patients, with the accompanying risks of pulmonary edema and severe hypertension. Fourth, the development of progressive post-transplant oliguria and ARF in otherwise hemodynamically stable patients with SRNS as their original disease should not lead to aggressive and potentially dangerous interventions such as arteriography or re-exploration, unless compelling evidence of a vascular catastrophe can be confirmed by less invasive methods such as an isotopic renal blood flow study. Fifth, SRNS patients with ARF and poor renal function require aliograft biopsies after 10 to 14 days and at similar intervals thereafter in order to detect the early development of acute rejection since this latter complication is difficult to diagnose in patients receiving dialysis support and since the risk of rejection is especially high. Finally, patients with recurrence of SRNS not having ARF should also be followed very closely for the development of acute rejection.
In summary, recurrence of steroid-resistant nephrotic syndrome is associated with a high risk of ARF, episodes of acute rejection, and increased graft loss from rejection. The pathogenic mechanisms underlying these clinical associations remain to be elucidated. consequent both to ARF and recurrence of SRNS is worthy of further study. However, the higher incidences of ARF and rejection in the SRNS patients with recurrence in our study could not be explained by more HLA mismatches or higher leukocyte panel reactivity in patients with recurrence than in those without recurrence or in controls.
These studies may have important implications regarding clinical decision making. The clinical ideas expressed here are not proven and, given the relative rarity of this condition, are difficult to subject to controlled observations. Nonetheless, they may be worthy of consideration. First, the high incidence of graft failure in patients with recurrence of SRNS might suggest that other approaches such as long-term dialysis therapy should be strongly considered for the patient with the specific factors predictive of a high risk for recurrence [8, 9, 23] .
